Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis Drops Genasense After Genta Declines To Modify Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Genta says it was approached by Aventis “on several occasions” after a negative Oncologic Drugs Advisory Committee review in May about modifying the financial terms of the oblimersen collaboration, “but we declined to make those accommodations.”
Advertisement

Related Content

Genta Postscript: Defunct Company’s Former President Charged With Insider Trading
Genta Returns To Old Territory With New Genasense Study
Genta Returns To Old Territory With New Genasense Study
Genta's Genasense Rolling NDA For Chronic Leukemia To Wrap In Fourth Quarter
Genasense Phase III Trial In Multiple Myeloma Fails
Genasense CLL Trial Meets Primary Endpoint, But Survival Benefit Not Yet Shown
Genasense CLL Trial Meets Primary Endpoint, But Survival Benefit Not Yet Shown
Genta Targeting Year-End Genasense NDA In Myeloma Or Lymphocytic Leukemia
Genasense Melanoma Progression-Free Survival Data Do Not Show "Real Effect," Cmte. Says
Genasense Melanoma Progression-Free Survival Data Do Not Show "Real Effect," Cmte. Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS058333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel